1. Antibody-drug Conjugate/ADC Related
  2. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC Related Products (14):

Cat. No. Product Name Effect Purity
  • HY-15575
    VcMMAE Inhibitor
    VcMMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
  • HY-19792
    Mertansine Inhibitor
    Mertansine is a tubulin inhibitor,inhibits the assemblyof microtubules by binding to tubulin, with a linker structure can create an antibody-drug conjugate (ADC).
  • HY-19812
    Acetylene-linker-Val-Cit-PABC-MMAE Inhibitor
    Acetylene-linker-Val-Cit-PABC-MMAE consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE), Acetylene-linker-Val-Cit-PABC-MMAE is an antibody drug conjugate.
  • HY-15741
    Mc-MMAE Inhibitor
    Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate (ADC).
  • HY-15578
    McMMAF Inhibitor
    Mc-MMAF is a protective group-conjugated MMAF. MMAF is a more potent drug than Monomethyl auristatin E (MMAE), but is charged and relatively membrane-impermeable, is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.
  • HY-101070
    SMCC-DM1 Inhibitor
    SMCC-DM1 is DM1 with a reactive linker SMCC to make antibody drug conjugate. DM1 (mertansine), a thiol-containing maytansinoid, is a potent microtubule-disrupting agent.
  • HY-100567
    MAL-di-EG-Val-Cit-PAB-MMAE Inhibitor
    MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), MAL-di-EG-Val-Cit-PAB-MMAE is an antibody drug conjugate.
  • HY-100566
    SuO-Val-Cit-PAB-MMAE Inhibitor
    SuO-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide SuO-Val-Cit-PAB.
  • HY-100374
    Val-Cit-PAB-MMAE Inhibitor
    Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide Val-Cit-PAB.
  • HY-15740
    Mc-MMAD Inhibitor
    Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate; Mc-MMAD is a protective group (maleimidocaproyl) -conjugated MMAD.
  • HY-15750
    Cys-mcMMAD Inhibitor
    Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.
  • HY-19813
    mDPR-Val-Cit-PAB-MMAE Inhibitor
    mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate.
  • HY-19811
    Fmoc-Val-Cit-PAB-MMAE Inhibitor
    Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), Fmoc-Val-Cit-PAB-MMAE is an antibody drug conjugate.
  • HY-15742
    Vc-MMAD Inhibitor
    Vc-MMAD consists the ADCs linker(Val-Cit) and potent tubulin inhibitor (MMAD), Vc-MMAD is an antibody drug conjugate.